Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases
Protection through 2039, ensuring long-term commercial exclusivity. NEW YORK, June 12, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies, today announced that they...